Skip to main content
. 2021 Aug 9;11(11):2764–2779. doi: 10.1158/2159-8290.CD-21-0094

Figure 2.

Figure 2. Distribution of the highest priority level target per patient over diagnoses. For each patient, only the highest priority level target is included. ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATRT, atypical teratoid rhabdoid tumor; DSRCT, desmoplastic round cell tumor; EPN, ependymoma; EWS, Ewing sarcoma; HGG, high-grade glioma (including diffuse-intrinsic pontine glioma); MB, medulloblastoma; MRT, malignant rhabdoid tumor; NB, neuroblastoma; NHL, non-Hodgkin lymphoma; OS, osteosarcoma; other heme, other hematologic malignancies; RMS, rhabdomyosarcoma; STS, soft-tissue sarcoma. *, Including four patients with a target not matching one of the priority levels.

Distribution of the highest priority level target per patient over diagnoses. For each patient, only the highest priority level target is included. ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATRT, atypical teratoid rhabdoid tumor; DSRCT, desmoplastic round cell tumor; EPN, ependymoma; EWS, Ewing sarcoma; HGG, high-grade glioma (including diffuse-intrinsic pontine glioma); MB, medulloblastoma; MRT, malignant rhabdoid tumor; NB, neuroblastoma; NHL, non-Hodgkin lymphoma; OS, osteosarcoma; other heme, other hematologic malignancies; RMS, rhabdomyosarcoma; STS, soft-tissue sarcoma. *, Including four patients with a target not matching one of the priority levels.